These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21480824)

  • 1. Motor complications, levodopa metabolism and progression of Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):847-55. PubMed ID: 21480824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of homocysteine in the treatment of Parkinson's disease.
    Müller T
    Expert Rev Neurother; 2008 Jun; 8(6):957-67. PubMed ID: 18505360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.
    Müller T
    Expert Rev Neurother; 2013 Jun; 13(6):707-18. PubMed ID: 23739007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
    Szadejko K; Szabat K; Ludwichowska A; Sławek J
    Przegl Lek; 2013; 70(7):443-7. PubMed ID: 24167945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
    Dézsi L; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications and limitations of drug therapy for Parkinson's disease.
    Jankovic J
    Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-related motor complications--phenomenology.
    Fox SH; Lang AE
    Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.
    Mancini F; Comi C; Oggioni GD; Pacchetti C; Calandrella D; Coletti Moja M; Riboldazzi G; Tunesi S; Dal Fante M; Manfredi L; Lacerenza M; Cantello R; Antonini A
    Parkinsonism Relat Disord; 2014 Jan; 20(1):27-31. PubMed ID: 24099722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
    Zhu BT
    Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Müller T
    Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.